Massive Intra‐Abdominal Pseudotumor in a Patient With Hemophilia A Treated With Emicizumab: A Case Report

Clinical Case Reports 2026 Open access

Read full text
Authors: C. J. Kilach, Cyrus Njuguna, Festus Muigai Njuguna, C. M. Wanjiku, K. F. Molitor, I. A. Janson, S. M. Mbunya, A. D. Shapiro, Jeanne Sagar, A. Greist
DOI: 10.1002/ccr3.71789
Cited by: 0
References: 9

Abstract

Hemophilic pseudotumors, a rare complication of bleeding disorders, are more common in settings with limited access to clotting factor concentrates. Subcutaneous emicizumab, a relatively novel therapy for hemophilia A, was investigated for its ability to stabilize an inoperable pseudotumor in a patient with factor VIII deficiency in an under-resourced setting.

Fields of Study & Subjects

Hemophilia Treatment and Research Platelet Disorders and Treatments Coagulation Bradykinin Polyphosphates and Angioedema

Publication details

Journal / source
Clinical Case Reports
Volume
14
Issue
1
Pages
e71789–e71789
Publication date
1 January 2026
Language
EN